Utilization of Standard Therapy and Adjunctive Isosorbide Dinitrate Pump with Clinical Outcomes in Acute Heart Failure Patients
DOI:
https://doi.org/10.3889/oamjms.2022.9376Keywords:
Standard therapy, ISDN pump, Acute heart failure, Length of hospitalization, NEWS 2Abstract
-
BACKGROUND: Acute heart failure is a life-threatening medical condition. Thus, effective therapy is very important for this case. Utilization of standard therapy and adjunctive isosorbide dinitrate (ISDN) pump play an important role in reducing mortality, length of hospitalization, and national early warning score – NEWS 2. However, the research on the utilization of the ISDN pump as adjunctive therapy is still limited.
AIM: This study aimed to analyze the association between utilization of standard therapy and adjunctive ISDN pump with clinical outcomes (mortality, length of hospitalization, and NEWS 2) in patients with acute heart failure.
METHODS: This was a cohort retrospective observational study. The purposive sampling technique was utilized to select the acute heart failure patients in UNS Sukoharjo Hospital. All the data were obtained from medical records. Logistic regression was used to analyze the data.
RESULTS: A total of 94 patients were included as the samples. There was a significant association between the utilization of standard therapy (OR=7.9; CI 95%= 3.1–20.4; p < 0.001) or ISDN pump (OR=0.3; CI 95%= 0.1–0.7; p < 0.001) with the length of hospitalization. However, there was no significant association between the utilization of standard therapy (OR=1.1; CI 95%= 0.2–6.6; p = 0.9) and ISDN pump (OR=0.2; CI 95%= 0.02–1.6; p = 0.1) with NEWS 2 on patients with acute heart failure.
CONCLUSION: There was a significant association between the utilization of standard therapy and ISDN pump with the length of hospitalization.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Kurmani S, Squire I. Acute heart failure: Definition, classification and epidemiology. Curr Heart Fail Rep. 2017;14(5):385-92. https://doi.org/10.1007/s11897-017-0351-y PMid:28785969 DOI: https://doi.org/10.1007/s11897-017-0351-y
Pellicori P, Kaur K, Clark AL. Fluid management in patients with chronic heart failure. Card Fail Rev. 2015;1(2):90-5. PMid:28785439
Reyes EB, Ha JW, Firdaus I, Ghazi AM, Phrommintikul A, Sim D, et al. Heart failure across Asia: Same healthcare burden but differences in organization of care. Int J Cardiol. 2016;223:163-7. https://doi.org/10.1016/j.ijcard.2016.07.256 PMid:27541646 DOI: https://doi.org/10.1016/j.ijcard.2016.07.256
Riskesdas. Hasil Utama Riskesdas 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan; 2018.
Kemenkes RI. Profil Penyakit Tidak Menular Tahun 2016. Jakarta: Kementerian Kesehatan RI; 2017.
Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7-11. PMid:28785469 DOI: https://doi.org/10.15420/cfr.2016:25:2
Krittayaphong R, Yadee J, Permsuwan U. Cost-effectiveness analysis of the adjunctive therapy of ivabradine for the treatment of heart failure with reduced ejection fraction. Clin Outcomes Res. 2019;11:767-77. https://doi.org/10.2147/ceor.s226568 PMid:31824183 DOI: https://doi.org/10.2147/CEOR.S226568
Chambord J, Attivi D, Thuus V, Zeghmouli C, Gibaud S. The effect of intravenous isosorbide dinitrate in acute decompensated heart failure in hospital. Int J Clin Pharm. 2017;39(3):536-41. https://doi.org/10.1007/s11096-017-0459-x PMid:28374342 DOI: https://doi.org/10.1007/s11096-017-0459-x
Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30-41. https://doi.org/10.1038/nrcardio.2010.165 PMid:21060326 DOI: https://doi.org/10.1038/nrcardio.2010.165
Danielsen R, Thorgeirsson G, Einarsson H, Ólafsson Ö, Aspelund T, Harris TB, et al. Prevalence of heart failure in the elderly and future projections: The AGES-Reykjavík study. Scand Cardiovasc J. 2017;51(4):183-9. https://doi.org/10.1080/14017431.2017.1311023 PMid:28366010 DOI: https://doi.org/10.1080/14017431.2017.1311023
Buddeke J, Bots ML, van Dis I, Visseren FL, Hollander M, Schellevis FG, et al. Comorbidity in patients with cardiovascular disease in primary care: A cohort study with routine healthcare data. Br J Gen Pract. 2019;69(683):e398-406. https://doi.org/10.3399/bjgp19x702725 PMid:31064742 DOI: https://doi.org/10.3399/bjgp19X702725
Machaj F, Dembowska E, Rosik J, Szostak B, Mazurek-Mochol M, Pawlik A. New therapies for the treatment of heart failure: A summary of recent accomplishments. Ther Clin Risk Manag. 2019;15:147-55. https://doi.org/10.2147/tcrm.s179302 PMid:30774351 DOI: https://doi.org/10.2147/TCRM.S179302
Alzahri MS, Rohra A, Peacock WF. Nitrates as a treatment of acute heart failure. Card Fail Rev. 2016;2(1):51-5. PMid:28785453 DOI: https://doi.org/10.15420/cfr.2016:3:3
Whellan DJ, Zhao X, Hernandez AF, Liang L, Peterson ED, Bhatt DL, et al. Predictors of hospital length of stay in heart failure: Findings from get with the guidelines. J Card Fail. 2011;17(8):649-56. https://doi.org/10.1016/j.cardfail.2011.04.005 PMid:21807326 DOI: https://doi.org/10.1016/j.cardfail.2011.04.005
White SM, Hill A. A heart failure initiative to reduce the length of stay and readmission rates. Prof Case Manag. 2014;19(6):276-84. https://doi.org/10.1097/ncm.0000000000000059 PMid:25271947 DOI: https://doi.org/10.1097/NCM.0000000000000059
Butler J, Yang M, Manzi MA, Hess GP, Patel MJ, Rhodes T, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73(8):935-44. https://doi.org/10.1016/j.jacc.2018.11.049 PMid:30819362 DOI: https://doi.org/10.1016/j.jacc.2018.11.049
Ferdinand KC, Elkayam U, Mancini D, Ofili E, Piña I, Anand I, et al. Use of isosorbide dinitrate and hydralazine in African- Americans with heart failure 9 years after the African American heart failure trial. Am J Cardiol. 2014;114(1):151-9. https://doi.org/10.1016/j.amjcard.2014.04.018 PMid:24846808 DOI: https://doi.org/10.1016/j.amjcard.2014.04.018
Cole RT, Kalogeropoulos AP, Georgiopoulou VV., Gheorghiade M, Quyyumi A, Yancy C, et al. Hydralazine and isosorbide dinitrate in heart failure: Historical perspective, mechanisms, and future directions. Circulation. 2011;123(21):2414-22. https://doi.org/10.1161/circulationaha.110.012781 PMid:21632515 DOI: https://doi.org/10.1161/CIRCULATIONAHA.110.012781
Ziaeian B, Fonarow GC, Heidenreich PA. Clinical effectiveness of hydralazine-isosorbide dinitrate in African-American patients with heart failure. JACC Hear Fail. 2017;5(9):632-9. https://doi.org/10.1016/j.jchf.2017.04.008 PMid:28711446 DOI: https://doi.org/10.1016/j.jchf.2017.04.008
Khazanie P, Liang L, Curtis LH, Butler J, Eapen ZJ, Heidenreich PA, et al. Clinical effectiveness of hydralazine-isosorbide dinitrate therapy in patients with heart failure and reduced ejection fraction: Findings from the get with the guidelines-heart failure registry. Circ Heart Fail. 2016;9(2):e002444. https://doi.org/10.1161/circheartfailure.115.002444 PMid:26867758 DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.115.002444
Gupta D, Georgiopoulou VV, Kalogeropoulos AP, Marti CN, Yancy CW, Gheorghiade M, et al. Nitrate therapy for heart failure: Benefits and strategies to overcome tolerance. JACC Heart Fail. 2013;1(3):183-91. https://doi.org/10.1016/j.jchf.2013.03.003 PMid:24621868 DOI: https://doi.org/10.1016/j.jchf.2013.03.003
Bhimaraj A. Remote monitoring of heart failure patients. Methodist Debakey Cardiovasc J 2013;9(1):26-31. https://doi.org/10.14797/mdcj-9-1-26 PMid:23519115 DOI: https://doi.org/10.14797/mdcj-9-1-26
Burnett H, Earley A, Voors AA, Senni M, McMurray JJ, Deschaseaux C, et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: A network meta-analysis. Circ Heart Fail. 2017;10(1):e003529. https://doi.org/10.1161/circheartfailure.116.003529 PMid:28087688 DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.116.003529
Echols MR, Yancy CW. Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure. Vasc Health Risk Manag. 2006;2(4):423-31. https://doi.org/10.2147/vhrm.2006.2.4.423 PMid:17323596 DOI: https://doi.org/10.2147/vhrm.2006.2.4.423
Ramani GV, Uber PA, Mehra MR. Chronic heart failure: Contemporary diagnosis and management. Mayo Clin Proc. 2010;85(2):180-95. https://doi.org/10.4065/mcp.2009.0494 PMid:20118395 DOI: https://doi.org/10.4065/mcp.2009.0494
Freund Y, Delerme S, Boddaert J, Baker E, Riou B, Ray P. Isosorbide dinitrate bolus for heart failure in elderly emergency patients: A retrospective study. Eur J Emerg Med. 2011;18(5):272-5. https://doi.org/10.1097/mej.0b013e328345d72a PMid:21499108 DOI: https://doi.org/10.1097/MEJ.0b013e328345d72a
Tsujimoto T, Kajio H. Use of nitrates and risk of cardiovascular events in patients with heart failure with preserved ejection fraction. Mayo Clin Proc. 2019;94(7):1210-20. https://doi.org/10.1016/j.mayocp.2018.11.032 PMid:31272569 DOI: https://doi.org/10.1016/j.mayocp.2018.11.032
Rodriguez F, Wang Y, Johnson CE, Foody JM. National patterns of heart failure hospitalizations and mortality by sex and age. J Card Fail. 2013;19(8):542-9. https://doi.org/10.1016/j.cardfail.2013.05.016 PMid:23910583 DOI: https://doi.org/10.1016/j.cardfail.2013.05.016
Molla S, Yitayal M, Amare G. Health-Related quality of life and associated factors among adult patients with heart failure in wolaita zone governmental hospitals, Southern Ethiopia. Risk Manag Healthc Policy. 2021;14:263-71. https://doi.org/10.2147/rmhp.s288326 DOI: https://doi.org/10.2147/RMHP.S288326
Stewart GC, Cascino T, Richards B, Khalatbari S, Mann DL, Taddei-Peters WC, et al. Ambulatory advanced heart failure in women. JACC Heart Fail. 2019;7(7):602-11. https://doi.org/10.1016/j.jchf.2019.02.007 PMid:31078480 DOI: https://doi.org/10.1016/j.jchf.2019.02.007
Cascino TM, Kittleson MM, Lala A, Stehlik J, Palardy M, Pamboukian SV, et al. Comorbid conditions and health-related quality of life in ambulatory heart failure patients. Circ Heart Fail. 2020;13(5):e006858. https://doi.org/10.1161/circheartfailure.119.006858 PMid:32418478 DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.119.006858
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Ratih Puspita Febrinasari, Stepvia Stepvia, Yusuf Ari Mashuri (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
